Open

Phase 2 study for Patients with Advanced Melanoma

In this study, we want to learn if patients with advanced melanoma can stop treatment after 12 months of therapy.

Age & Gender

18 years ~ 99 years
Male, Female

Visit Availability

Standard business hours (M-F, 8-5)

Location

United States (Nationwide)

What will be asked of you

After being selected for the study, you will be asked about your medical history, have your vital signs taken, and asked questions about your general health. At various points in the study, you will receive a CT or MRI to determine your disease progression.

Incentives

Study medication

Total length of participation:
Unitll disease progression

Looking for Specific Volunteers

Able to participate:

You have advanced, unresectable melanoma
You are receiving standard of care treatment for your melanoma

Not eligible if:

You are receiving therapy other than anti-PD 1 regmine
You have detectable levels of the HIV,HPV, or HCV virus

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clinical Research
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Stergios Moschos
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Melanoma)

IRB Number

23-2548

ClinicalTrials.gov

NCT04462406

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.